UY31397A1 - Inhibidores de quinasa c-fms - Google Patents

Inhibidores de quinasa c-fms

Info

Publication number
UY31397A1
UY31397A1 UY31397A UY31397A UY31397A1 UY 31397 A1 UY31397 A1 UY 31397A1 UY 31397 A UY31397 A UY 31397A UY 31397 A UY31397 A UY 31397A UY 31397 A1 UY31397 A1 UY 31397A1
Authority
UY
Uruguay
Prior art keywords
cancer
compounds
diseases
inflammatory
osteoarthritis
Prior art date
Application number
UY31397A
Other languages
English (en)
Inventor
Mark J Wall
Sanath K Meegalla
Jinsheng Chen
Carl R Illig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31397A1 publication Critical patent/UY31397A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)

Abstract

La invención se refiere a compuestos de fórmula I: en donde Z, X, J, R2 y W se definen en la memoria descriptiva, así como a solvatos, hidratos, tautómeros y sales farmacéuticamente aceptables de dichos compuestos, que inhiben las proteínas tirosina quinasas, en especial la quinasa c-fms.También se proporcionan métodos para tratar enfermedades autoinmunes y enfermedades con un componente inflamatorio; para tratar metástasis de cáncer de ovario, cáncer de útero, cáncer de mama, cáncer de próstata, cáncer de pulmón, cáncer de colon, cáncer de estómago, leucemia de células pilosas; y para tratar el dolor, que incluye dolor esquelético causado por metástasis tumoral u osteoartritis, o dolor visceral, inflamatorio y neurogénico; así como osteoporosis, enfermedad de Paget y otras enfermedades en las cuales la reabsorción ósea media la morbilidad, que incluyen artritis reumatoidea y otras formas de artritis inflamatoria, osteoartritis, falla de prótesis, sarcoma osteolítico, mieloma y metástasis tumoral a los huesos, con los compuestos de fórmula I.
UY31397A 2007-10-17 2008-10-16 Inhibidores de quinasa c-fms UY31397A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98062307P 2007-10-17 2007-10-17

Publications (1)

Publication Number Publication Date
UY31397A1 true UY31397A1 (es) 2009-04-30

Family

ID=40352814

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31397A UY31397A1 (es) 2007-10-17 2008-10-16 Inhibidores de quinasa c-fms

Country Status (36)

Country Link
US (1) US8497376B2 (es)
EP (2) EP3208269B1 (es)
JP (1) JP5475672B2 (es)
KR (1) KR101559326B1 (es)
CN (1) CN101889009B (es)
AR (1) AR068892A1 (es)
AU (1) AU2008312540B2 (es)
BR (1) BRPI0817843B8 (es)
CA (1) CA2702898C (es)
CL (1) CL2008003068A1 (es)
CO (1) CO6270363A2 (es)
CR (1) CR11433A (es)
CY (2) CY1118717T1 (es)
DK (2) DK3208269T3 (es)
EA (1) EA018936B1 (es)
ES (2) ES2614754T3 (es)
HR (2) HRP20211593T1 (es)
HU (2) HUE031555T2 (es)
IL (1) IL205043A (es)
JO (1) JO3240B1 (es)
LT (2) LT3208269T (es)
MX (1) MX2010004263A (es)
MY (1) MY153951A (es)
NI (1) NI201000059A (es)
NZ (1) NZ584574A (es)
PA (1) PA8799701A1 (es)
PE (1) PE20090972A1 (es)
PL (2) PL2215079T3 (es)
PT (2) PT2215079T (es)
RS (2) RS62569B1 (es)
SI (2) SI2215079T1 (es)
TW (1) TWI440637B (es)
UA (1) UA99311C2 (es)
UY (1) UY31397A1 (es)
WO (1) WO2009052237A1 (es)
ZA (1) ZA201003429B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
KR101367645B1 (ko) 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP2016070B1 (en) * 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
US20120271046A1 (en) 2011-04-19 2012-10-25 Jeffrey Christopher S Nitrogen-containing heterocyclic compounds and methods of making the same
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (en) * 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
AU2013302468B2 (en) 2012-08-16 2017-08-24 Janssen Pharmaceutica Nv Substituted pyrazoles as N-type calcium channel blockers
AU2014235178A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv 4-cyano-N-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboxamide for the treatment of Hodgkin's lymphoma
HUE036925T2 (hu) * 2013-03-15 2018-08-28 Janssen Pharmaceutica Nv C-fms kináz inhibitorként használható helyettesített piridin származékok
MX2016002043A (es) * 2013-08-16 2016-05-26 Janssen Pharmaceutica Nv Imidazoles sustituidos como bloqueadores de canales de calcio tipo n.
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015094970A1 (en) * 2013-12-19 2015-06-25 Archer Daniels Midland Company Mono- and dialkyl ethers of furan-2,5-dimethanol and (tetra-hydrofuran-2,5-diyl)dimethanol and amphiphilic derivatives thereof
JP6537338B2 (ja) * 2015-04-24 2019-07-03 日東電工株式会社 核酸固相合成用リンカー及び担体
EP3414237B1 (de) * 2016-02-11 2020-12-23 Bayer CropScience Aktiengesellschaft Substituierte 2-oxyimidazolyl-carboxamide als schädlingsbekämpfungsmittel
TW201811326A (zh) * 2016-07-18 2018-04-01 比利時商健生藥品公司 ４－氰基－ｎ－（２－（４，４－二甲基環己－１－烯－１－基）－６－（２，２，６，６－四甲基四氫－２ｈ－哌喃－４－基）吡啶－３－基）－１ｈ－咪唑－２－甲醯胺之鹽形式
TWI752980B (zh) * 2016-07-18 2022-01-21 比利時商健生藥品公司 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型
WO2018160917A1 (en) 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
WO2020222109A1 (en) 2019-05-02 2020-11-05 Janssen Biotech, Inc. Csf-1/csf-1r gene set
CN110575450B (zh) * 2019-09-17 2023-03-31 遵义医科大学珠海校区 2,5-呋喃二甲醇在制备抗肿瘤药物中的应用
WO2021144360A1 (en) 2020-01-17 2021-07-22 F. Hoffmann-La Roche Ag Small molecule csf-1r inhibitors in therapeutic and cosmetic uses

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2466420A (en) 1947-11-26 1949-04-05 Eastman Kodak Co Ketene condensation products with aldehydes
US3226394A (en) 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
CH504416A (de) 1966-12-05 1971-03-15 Ciba Geigy Ag Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen
US4551540A (en) 1983-01-17 1985-11-05 Borg-Warner Chemicals, Inc. Substituted 2,5-dimethylpyrroles
US5190541A (en) 1990-10-17 1993-03-02 Boston Scientific Corporation Surgical instrument and method
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
WO1996011932A1 (en) 1994-10-14 1996-04-25 Smithkline Beecham Plc 2-(imidazol-4-yl)carbapeneme derivatives, intermediates thereof and use as antibacterials
JPH10506560A (ja) 1995-04-19 1998-06-30 シュナイダー（ユーエスエー）インク 薬品を放出する被覆されたステント
US6117432A (en) 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
AU711142B2 (en) 1995-12-08 1999-10-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5702390A (en) 1996-03-12 1997-12-30 Ethicon Endo-Surgery, Inc. Bioplar cutting and coagulation instrument
WO1998006700A1 (en) 1996-08-09 1998-02-19 Merck & Co., Inc. Stereoselective deoxygenation reaction
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
ATE252104T1 (de) 1996-12-20 2003-11-15 Tovarischestvo S Ogranichennoi Verfahren und gerät zur herstellung von 1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12- lid- hydrochlorid
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
NZ336233A (en) 1997-04-25 2001-01-26 Janssen Pharmaceutica Nv Phenyl substituted quinazolines on 4-position and 2-quinazolinone moiety bearing a carbon or nitrogen-linked imidazolyl moiety
TW491872B (en) 1997-05-27 2002-06-21 Ciba Sc Holding Ag Block oligomers containing l-hydrocarbyloxy-2,2,6,6-tetramethyl-4- piperidyl groups as stabilizers for lower polyolefin
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
CA2322798C (en) 1998-03-05 2008-05-13 Formula One Administration Limited Data communication system
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
AU5086499A (en) 1998-07-01 2000-01-24 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
JP2002520324A (ja) 1998-07-10 2002-07-09 メルク エンド カムパニー インコーポレーテッド 新規な血管形成インヒビター
ES2259237T3 (es) 1998-08-27 2006-09-16 Pfizer Products Inc. Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.
CA2341739C (en) 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
KR100712226B1 (ko) 1998-12-23 2007-04-27 얀센 파마슈티카 엔.브이. 1,2-어닐링된 퀴놀린 유도체
ES2206191T3 (es) 1999-01-11 2004-05-16 Princeton University Inhibidores de alta afinidad para validacion de dianas y usos de los mismos.
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
RU2260592C9 (ru) 1999-04-15 2017-04-07 Бристол-Маерс Сквибб Ко. Циклические ингибиторы протеинтирозинкиназ
EP1185559A2 (en) 1999-04-28 2002-03-13 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ATE449764T1 (de) 1999-12-28 2009-12-15 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
FR2803592A1 (fr) 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US6558385B1 (en) 2000-09-22 2003-05-06 Tissuelink Medical, Inc. Fluid-assisted medical device
US6692491B1 (en) 2000-03-24 2004-02-17 Scimed Life Systems, Inc. Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
WO2002032861A2 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
CN1582150B (zh) 2001-10-30 2011-09-07 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
KR100965519B1 (ko) 2001-12-27 2010-06-23 세라밴스 인코포레이티드 단백질 키나제 억제제로서 유용한 인돌리논 유도체
WO2003099796A1 (en) 2002-05-23 2003-12-04 Cytopia Pty Ltd Protein kinase inhibitors
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
BR0313397A (pt) 2002-08-14 2005-06-28 Vertex Pharmaceuticals Incorpo Inibidores de proteina cinase e usos destes
JP4613130B2 (ja) 2002-08-23 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ベンゾイミダゾールキノリノンおよびそれらの使用
AU2003258491A1 (en) 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
AU2003282726B2 (en) 2002-10-03 2010-10-07 Targegen, Inc. Vasculostatic agents and methods of use thereof
WO2004039782A1 (ja) 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
US7838527B2 (en) 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
DE60326646D1 (de) 2002-12-18 2009-04-23 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
MXPA05010945A (es) 2003-04-09 2005-11-25 Japan Tobacco Inc Compuesto pentaciclico heteroaromatico y uso medicinal del mismo.
US7427683B2 (en) 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
WO2004096795A2 (en) 2003-04-25 2004-11-11 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
US7790724B2 (en) 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
US20050113566A1 (en) 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
CA2533812C (en) 2003-07-28 2012-12-18 Smithkline Beecham Corporation Substituted cycloalkylidene compounds
EP1684750B1 (en) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0326601D0 (en) 2003-11-14 2003-12-17 Novartis Ag Organic compounds
EP1711497A1 (en) 2004-01-30 2006-10-18 AB Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
ATE437864T1 (de) * 2004-10-22 2009-08-15 Janssen Pharmaceutica Nv Aromatische amide als hemmer der c-fms-kinase
MX2007004784A (es) * 2004-10-22 2007-09-11 Johnson & Johnson Inhibidores de la c-fms cinasa.
US7662837B2 (en) 2004-10-22 2010-02-16 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
DE102005023588A1 (de) 2005-05-18 2006-11-23 Grünenthal GmbH Salze substituierter Allophansäureester und deren Verwendung in Arzneimitteln
US20060281769A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281771A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281755A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
CA2626623C (en) 2005-10-18 2016-08-30 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
US8674100B2 (en) 2006-04-20 2014-03-18 Janssen Pharmaceutica, N.V. Inhibitors of C-FMS kinase
EP2016070B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
KR101367645B1 (ko) 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물

Also Published As

Publication number Publication date
AU2008312540A1 (en) 2009-04-23
PL3208269T3 (pl) 2022-01-10
JO3240B1 (ar) 2018-03-08
EA018936B1 (ru) 2013-11-29
BRPI0817843A2 (pt) 2015-04-07
PA8799701A1 (es) 2009-05-15
EP2215079B1 (en) 2016-12-14
EP2215079A1 (en) 2010-08-11
JP5475672B2 (ja) 2014-04-16
TWI440637B (zh) 2014-06-11
CY1118717T1 (el) 2017-07-12
HUE056173T2 (hu) 2022-01-28
LT2215079T (lt) 2017-01-25
MY153951A (en) 2015-04-15
KR20100069711A (ko) 2010-06-24
IL205043A (en) 2015-07-30
RS55860B1 (sr) 2017-08-31
DK2215079T3 (en) 2017-02-13
HUE031555T2 (en) 2017-07-28
JP2011501752A (ja) 2011-01-13
EA201070480A1 (ru) 2010-10-29
SI3208269T1 (sl) 2021-11-30
IL205043A0 (en) 2010-11-30
TW200932738A (en) 2009-08-01
ES2905118T3 (es) 2022-04-07
ES2614754T3 (es) 2017-06-01
AU2008312540B2 (en) 2014-03-27
HRP20170393T1 (hr) 2017-05-05
PL2215079T3 (pl) 2017-06-30
SI2215079T1 (sl) 2017-05-31
PE20090972A1 (es) 2009-07-13
WO2009052237A1 (en) 2009-04-23
HRP20211593T1 (hr) 2022-03-18
CO6270363A2 (es) 2011-04-20
CL2008003068A1 (es) 2009-03-06
CN101889009A (zh) 2010-11-17
NI201000059A (es) 2010-09-13
EP3208269B1 (en) 2021-09-15
BRPI0817843B8 (pt) 2021-05-25
CR11433A (es) 2011-01-14
AR068892A1 (es) 2009-12-16
LT3208269T (lt) 2021-11-10
PT3208269T (pt) 2021-12-09
UA99311C2 (en) 2012-08-10
PT2215079T (pt) 2017-03-23
NZ584574A (en) 2011-12-22
EP3208269A1 (en) 2017-08-23
CA2702898C (en) 2016-10-11
RS62569B1 (sr) 2021-12-31
CN101889009B (zh) 2014-10-29
BRPI0817843B1 (pt) 2019-01-02
DK3208269T3 (da) 2021-10-11
CY1124721T1 (el) 2022-07-22
US20090105296A1 (en) 2009-04-23
KR101559326B1 (ko) 2015-10-12
US8497376B2 (en) 2013-07-30
ZA201003429B (en) 2011-08-31
CA2702898A1 (en) 2009-04-23
MX2010004263A (es) 2010-05-03

Similar Documents

Publication Publication Date Title
UY31397A1 (es) Inhibidores de quinasa c-fms
UA88648C2 (en) Inhibitors of c-fms kinase
UA93085C2 (en) Inhibitors of c-fms kinase
PT2021335E (pt) Compostos heterocíclicos como inibidores de c-fms quinase
ATE437864T1 (de) Aromatische amide als hemmer der c-fms-kinase
ECSP077409A (es) Inhibidores de la c-fms cinasa
CY1120338T1 (el) Εκλεκτικοι ρυθμιστες υποδοχεα φωσφορικης σφιγγοσινης 1 και μεθοδοι χειρομορφικης συνθεσης
NI200900032A (es) Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3
CY1120002T1 (el) Παραγωγα πυραζινης χρησιμα ως αναστολεις κινασης atr
CY1112142T1 (el) Κυκλοπεντα [d] πυριμιδινες ως αναστολεις της κινασης πρωτεϊνης του ακτ
UA107796C2 (en) Tetracyclic compound
EA201400575A1 (ru) Способы получения ингибиторов jak киназ и родственных промежуточных соединений
CY1112117T1 (el) Υδροξυλιωμενες και μεθοξυλιωμενες κυκλοπεντα[d]πυριμιδινες ως αναστολεις ακτ πρωτεϊνικης κινασης
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
PT1761520E (pt) Inibidores de quinase
BR112022009390A2 (pt) Síntese melhorada de composto inibidor de kras g12c
DOP2005000010A (es) Inhibidores de quinasa
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
CL2020001930A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas.
CY1117805T1 (el) Αντιμετωπιση οστεοπορωσης
CO6331435A2 (es) Nuevas formas polimórficas de dihidróheno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-3{-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparación
TH150114A (th) สารยับยั้ง c-fms ไคเนส
PL430989A1 (pl) Sposób otrzymywania długołańcuchowych arylopiperazyn
CU24049B1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)
TH83708B (th) ตัวยับยั้ง c-fms ไคเนส